Skip to main content
. 2013 Feb 20;121(5):613–618. doi: 10.1289/ehp.1206066

Figure 3.

Figure 3

Effect of TCDD on promoter activity (A,B) and mRNA levels (C) in SK‑N‑SH cells. (A, B) The human ACHE promoter–reporter construct (pAChE-Luc) was transiently transfected into SK‑N‑SH cells 1 day before treatment; after 24 hr of treatment, promoter activity was determined by luciferase assays. (A) Transfected cells were incubated with TCDD (10–11 to 10–9 M) or with 0.1% DMSO (control). (B) Transfected cells were pretreated with 10–6 M CH223191 (AhR inhibitor) for 3 hr and then incubated for 24 hr with 10–9 M TCDD or 0.01% DMSO. (C) Expression level of AChE transcripts (AChET and AChER variant) and PRiMA transcripts determined by real-time PCR analysis of total RNA extracted from cells treated with 10–9 M TCDD or 0.1% DMSO. See “Materials and Methods” for additional details. Values were calculated as a percentage of control and are expressed as mean ± SE (n = 3); each independent sample was tested in triplicate. *p < 0.05 compared with control by one-way ANOVA with Bonferroni test. #p < 0.05 compared with TCDD by one-way ANOVA with Bonferroni test.